Why Is BELITE BIO INC ADR (BLTE) Stock Moving Today?

Belite Bio (BLTE) shares fell 7.59% to $157.06. The primary driver was the release of third-quarter financial results, which showed a non-GAAP EPS of -$0.60, beating estimates by $0.17 despite the company remaining unprofitable.

What Happened

Belite Bio reported unaudited third-quarter 2026 financial results on November 12, 2026. The company posted a non-GAAP EPS of -$0.60, which exceeded the consensus estimate of -$0.77. As of September 30, 2026, the company held $271.3 million in cash and cash equivalents. Management outlined regulatory timing and commercial plans for its Stargardt drug during the earnings call. The New Drug Application for tinlarebant in Stargardt disease type 1 was granted priority review by the U.S. Food and Drug Administration in August 2026.

Following the report, Leerink raised its price target to $215 from $185. StoneX reiterated a Buy rating with a $217 price target. The stock had previously been uplisted to the Nasdaq Global Select Market.

What The Data Shows

The stock opened at $172.80, a 1.7% gap from the prior close of $169.96. It reached a session high of $174.25 at 8:30 AM ET before declining to a session low of $157.06 at 9:50 AM ET. Volume was 0.0M shares, which is 0.2x the 3-month daily average. The company has a market cap of $6.3B and is unprofitable with a trailing twelve-month EPS of -2.74. The 52-week range is $105.88 to $200.00. Over the last eight sessions, the stock moved 11.7% from $152.17 to $169.96.

Recent insider activity includes three sales totaling $32.0M in the last 90 days. Chief Medical Officer Scholl Hendrik Peter sold on October 1, 2026. Chief Financial Officer Chuang Hao-Yuan and Chief Executive Officer Lin Yu-Hsin both sold on September 4, 2026. The stock printed four fresh 52-week lows on November 13, 2026.

What To Watch

Investors will monitor the company's progress with the FDA priority review for tinlarebant. The upcoming PDUFA target date for the Stargardt disease drug remains a key catalyst for the stock's valuation.

Why is BLTE stock moving today?

BELITE BIO INC ADR (BLTE) is drawing unusual attention today. Our newswire has captured 6 stories on BLTE across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100). The most recent driver: "Belite Bio price target raised to $215 from $185 at Leerink" (The Fly).

Is BLTE a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BLTE coverage reads 59/100 over 6 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.